Cargando…
Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402915/ https://www.ncbi.nlm.nih.gov/pubmed/34452413 http://dx.doi.org/10.3390/v13081548 |
_version_ | 1783745905608884224 |
---|---|
author | Gradissimo, Ana Shankar, Viswanathan Wiek, Fanua St. Peter, Lauren Studentsov, Yevgeniy Nucci-Sack, Anne Diaz, Angela Pickering, Sarah Schlecht, Nicolas F. Burk, Robert D. |
author_facet | Gradissimo, Ana Shankar, Viswanathan Wiek, Fanua St. Peter, Lauren Studentsov, Yevgeniy Nucci-Sack, Anne Diaz, Angela Pickering, Sarah Schlecht, Nicolas F. Burk, Robert D. |
author_sort | Gradissimo, Ana |
collection | PubMed |
description | The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccine longitudinal cohort at Mount Sinai Adolescent Health Center in Manhattan, NY. We performed a nested case–control study of 43 cases with incident detection of cervical HPV16 (n = 26) or HPV31 (n = 17) DNA who had completed the full set of immunizations of the quadrivalent HPV vaccine (4vHPV). Two control individuals whom had received three doses of the vaccine (HPV16/31-negative) were selected per case, matched on age at the first dose of vaccination and follow-up time in the study: a random control, and a high-risk control that was in the upper quartile of a sexual risk behavior score. We conducted an enzyme-linked immunosorbent assay (ELISA) for the detection of immunoglobulin G (IgG) antibodies specific to anti-HPV16 virus-like particles (VLPs). The results suggest that the average log antibody titers were higher among high-risk controls than the HPV16/31 incident cases and the randomly selected controls. We show a prospective association between anti-HPV16 VLP titers and the acquisition of an HPV16/31 incident infection post-receiving three doses of 4vHPV vaccine. |
format | Online Article Text |
id | pubmed-8402915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84029152021-08-29 Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection Gradissimo, Ana Shankar, Viswanathan Wiek, Fanua St. Peter, Lauren Studentsov, Yevgeniy Nucci-Sack, Anne Diaz, Angela Pickering, Sarah Schlecht, Nicolas F. Burk, Robert D. Viruses Article The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccine longitudinal cohort at Mount Sinai Adolescent Health Center in Manhattan, NY. We performed a nested case–control study of 43 cases with incident detection of cervical HPV16 (n = 26) or HPV31 (n = 17) DNA who had completed the full set of immunizations of the quadrivalent HPV vaccine (4vHPV). Two control individuals whom had received three doses of the vaccine (HPV16/31-negative) were selected per case, matched on age at the first dose of vaccination and follow-up time in the study: a random control, and a high-risk control that was in the upper quartile of a sexual risk behavior score. We conducted an enzyme-linked immunosorbent assay (ELISA) for the detection of immunoglobulin G (IgG) antibodies specific to anti-HPV16 virus-like particles (VLPs). The results suggest that the average log antibody titers were higher among high-risk controls than the HPV16/31 incident cases and the randomly selected controls. We show a prospective association between anti-HPV16 VLP titers and the acquisition of an HPV16/31 incident infection post-receiving three doses of 4vHPV vaccine. MDPI 2021-08-05 /pmc/articles/PMC8402915/ /pubmed/34452413 http://dx.doi.org/10.3390/v13081548 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gradissimo, Ana Shankar, Viswanathan Wiek, Fanua St. Peter, Lauren Studentsov, Yevgeniy Nucci-Sack, Anne Diaz, Angela Pickering, Sarah Schlecht, Nicolas F. Burk, Robert D. Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection |
title | Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection |
title_full | Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection |
title_fullStr | Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection |
title_full_unstemmed | Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection |
title_short | Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection |
title_sort | anti-hpv16 antibody titers prior to an incident cervical hpv16/31 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402915/ https://www.ncbi.nlm.nih.gov/pubmed/34452413 http://dx.doi.org/10.3390/v13081548 |
work_keys_str_mv | AT gradissimoana antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection AT shankarviswanathan antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection AT wiekfanua antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection AT stpeterlauren antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection AT studentsovyevgeniy antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection AT nuccisackanne antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection AT diazangela antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection AT pickeringsarah antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection AT schlechtnicolasf antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection AT burkrobertd antihpv16antibodytiterspriortoanincidentcervicalhpv1631infection |